Paul Tudor Jones’s Regeneron Pharmaceuticals REGN Stock Holding History

Paul Tudor Jones’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.98M	Buy	+12,800	New	+$8.71M	0.01%	962
2026 Q1	–	Sell	-25,500	Closed	-$19.7M	–	4161
2025 Q4	$19.7M	Sell	25,500 -16,500	-39%	-$11.2M	0.04%	423
2025 Q3	$23.6M	Buy	42,000 +7,300	+21%	+$4.13M	0.04%	366
2025 Q2	$18.2M	Buy	34,700 +17,200	+98%	+$9.6M	0.04%	369
2025 Q1	$11.1M	Sell	17,500 -500	-3%	-$344K	0.04%	415
2024 Q4	$12.8M	Buy	18,000 +10,500	+140%	+$8.81M	0.05%	266
2024 Q3	$7.88M	Buy	+7,500	New	+$8.35M	0.03%	514

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Paul Tudor Jones's REGN Position: Q3 2025 in Review

Paul Tudor Jones sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 84,550 shares — an estimated $47.8M sold.

Paul Tudor Jones first reported a position in REGN in Q2 2013 and held it in 26 quarters. The position peaked at $80M in Q1 2025. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Paul Tudor Jones reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Paul Tudor Jones sold 84,550 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $47.8M.
Paul Tudor Jones first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 26 quarters.
Paul Tudor Jones's Regeneron Pharmaceuticals position peaked at $80M in Q1 2025.
1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Tudor Investment Corp's 13F filing for Q3 2025, filed 14 Nov 2025.